Pfizer Triples Down On CDK Inhibition In Breast, Other Cancers

CDK2, CDK4, CDK2/4/6 Drugs Now In Early Trials

 
• By Mandy Jackson
  
Digital 3d illustration of cancer cells in human body
Pfizer looks to strengthen its breast cancer position with additional CDK inhibitors • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category